EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment.
about
Network analysis of ChIP-Seq data reveals key genes in prostate cancer.Why imatinib remains an exception of cancer research.Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.Decline in Arylsulfatase B Expression Increases EGFR Expression by Inhibiting the Protein Tyrosine Phosphatase SHP2 and Activating JNK in Prostate Cells.
P2860
EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
EGFR Targeting in Hormone-Refr ...... l and Prospects for Treatment.
@ast
EGFR Targeting in Hormone-Refr ...... l and Prospects for Treatment.
@en
type
label
EGFR Targeting in Hormone-Refr ...... l and Prospects for Treatment.
@ast
EGFR Targeting in Hormone-Refr ...... l and Prospects for Treatment.
@en
prefLabel
EGFR Targeting in Hormone-Refr ...... l and Prospects for Treatment.
@ast
EGFR Targeting in Hormone-Refr ...... l and Prospects for Treatment.
@en
P2093
P2860
P356
P1433
P1476
EGFR Targeting in Hormone-Refr ...... l and Prospects for Treatment.
@en
P2093
Gerard Milano
Jean Louis Fischel
Jean-Marc Ferrero
Olivier Guérin
P2860
P304
P356
10.3390/PH3072238
P577
2010-07-19T00:00:00Z